Join Arrowhead Pharmaceuticals for Part II of its 2024 Summer Series of R&D Webinars, featuring Christie M. Ballantyne, MD, FACP, FACC (Baylor College of Medicine). Following Dr. Ballantyne’s presentation, Arrowhead management will provide updates on two of its key cardiometabolic programs:

• Plozasiran, an RNAi therapeutic designed to reduce production of Apolipoprotein C-III (ApoC3), currently being investigated in the MUIR Phase 2b clinical study in patients with mixed dyslipidemia, the PALISADE Phase 3 clinical study in patients with familial chylomicronemia syndrome, and the Phase 3 SHASTA-3 and SHASTA-4 studies in patients with severe hypertriglyceridemia.
• Zodasiran, an RNAi therapeutic designed to reduce production of angiopoietin-like protein (ANGPTL3), currently being investigated in the ARCHES-2 Phase 2b clinical study in patients with mixed dyslipidemia and the GATEWAY Phase 2 study in patients with homozygous familial hypercholesterolemia.

A live question and answer session will follow the formal presentation.